A Randomized, Open-Label Study Exploring a Simplified Kaletra (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Trial Profile

A Randomized, Open-Label Study Exploring a Simplified Kaletra (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2009

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz; Lamivudine/zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 15 Aug 2009 Tolerability results, with respect to drug-induced osteoporosis, have been reported in the Journal of Acquired Immune Deficiency Syndromes.
    • 01 Mar 2009 Results published in AIDS Research and Human Retroviruses.
    • 15 Jul 2008 Primary endpoint results published in The Journal of Infectious Diseases in July 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top